[Comment] U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis

Upadacitinib is a targeted, synthetic, oral, small molecule with preferential inhibition for JAK1 receptors. It is now one of a rapidly growing list of licensed medical therapies for ulcerative colitis, and well conducted clinical trials have provided important short-term data about its efficacy and safety.1–3 Despite the chronic, life-long nature of ulcerative colitis,4 longer-term data from clinical trials are scarce—a problem shared with many other areas of medicine.5 Therefore, data from the U-ACTIVATE long-term extension trial are welcome.



Source link